Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00626158 · ClinicalTrials.gov registry record · Phase 1
Gemcitabine and Capecitabine to Treat Patients With Advanced Pancreatic and Biliary Cancers
A Phase 1 study of Pancreatic Cancer and Biliary Cancer, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 1
- Development phase
- 45
- Enrollment target
- 2
- Study locations
NCT00626158 is a Phase 1 study of Pancreatic Cancer and Biliary Cancer that has completed, run by University of California, San Francisco. The registered enrollment target is 45 participants, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (89% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT00626158, a Phase 1 study of Pancreatic Cancer and Biliary Cancer, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 45 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to find out what effects gemcitabine plus capecitabine has on patients with pancreatic or biliary cancer, and to determine the optimal dose that can be given safely of these two drugs together (called the maximum tolerated dose). Gemcitabine and capecitabine are two chemotherapy drugs used to treat pancreatic and biliary cancer. These two drugs used together are considered an acceptable standard of care for pancreatic and biliary cancers. However, in this study the dose and dosing schedule will be changed, in the hopes that the drugs will have more effect with fewer side effects than when given in the standard way.
Conditions Studied
Interventions
- DRUG gemcitabine
- DRUG capecitabine
Study Locations (2)
California
- UCSF Helen Diller Family Comprehensive Cancer Center - San Francisco
Utah
- Huntsman Cancer Center, University of Utah - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2008-02 |
| Est. Completion | 2010-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00626158
The ClinicalTrials.gov registry entry for NCT00626158 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (89% lower). The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Pancreatic Cancer appearing as the primary indexed condition, and to 2 interventions - of which gemcitabine is the first listed.
NCT00626158 reports 2 study locations spanning 2 distinct geographic areas - top geographies include California, Utah.
Frequently Asked Questions
What is clinical trial NCT00626158 about?
NCT00626158 is a clinical study titled "Gemcitabine and Capecitabine to Treat Patients With Advanced Pancreatic and Biliary Cancers". The purpose of this study is to find out what effects gemcitabine plus capecitabine has on patients with pancreatic or biliary cancer, and to determine the optimal dose that can be given safely of these two drugs together (called the maximum tolerated dose). Gemcitabine and capecitabine are two chem...
What is the current status of trial NCT00626158?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 45 participants. The study started on 2008-02. Estimated completion is 2010-12.
What conditions does trial NCT00626158 study?
This clinical trial studies the following conditions: Pancreatic Cancer, Biliary Cancer.
What interventions are being tested in trial NCT00626158?
The interventions under investigation include: gemcitabine (DRUG), capecitabine (DRUG).
Who is sponsoring clinical trial NCT00626158?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00626158 being conducted?
This trial has 2 study locations across California, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer
RECRUITING · Phase 1
-
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
RECRUITING · Phase 1
-
EUS RFA for Treatment of Pancreatic Ductal Adenocarcinoma (PDAC)
RECRUITING · Phase 1
-
SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells
RECRUITING · Phase 1
-
64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.